Developing antibodies that act on regulatory T cells (Tregs) via either novel or validated targets

Tregs can substantially inhibit various immune responses enabling tumour cells to escape detection. BioInvent is currently developing antibodies to modulate specific currently undetermined Treg targets and functions as well as for known targets such as OX-40 and 4-1BB.

BioInvent is currently working to expand the pool of antibodies and targets that have been shown to be associated with Treg specificity and Treg depleting activity.

BioInvent is working in cooperation with Cancer Research Technology and the University of Southampton in the UK to develop new immunotherapeutic cancer drugs based on antibodies that target OX-40 and 4-1BB, two known co-receptors that help activate T cells, to produce long-lasting anti-tumour immune responses.